☰

Ming-Hui Chen - Publications

Affiliations: 
University of Connecticut, Storrs, CT, United States 
Area:
Statistics
Tree Info Similar researchers PubMed Report error

266 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Walburn T, Chen MH, Loffredo M, McMahon E, Orio PF, Nguyen PL, D'Amico AV, Sayan M. Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trial. Cancer. PMID 38427287 DOI: 10.1002/cncr.35274  0.33
2023 Sayan M, Huang J, Xie W, Chen MH, Loffredo M, McMahon E, Orio P, Nguyen P, D'Amico AV. Risk of Short-Term Prostate-Specific Antigen Recurrence and Failure in Patients With Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. Jama Network Open. 6: e2336390. PMID 37801315 DOI: 10.1001/jamanetworkopen.2023.36390  0.309
2023 Tilki D, Chen MH, Wu J, Huland H, Graefen M, Mohamad O, Cowan JE, Feng FY, Carroll PR, D'Amico AV. Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2202489. PMID 36857638 DOI: 10.1200/JCO.22.02489  0.327
2022 Tilki D, Chen MH, Wu J, Huland H, Graefen M, D'Amico AV. Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102800. PMID 35290082 DOI: 10.1200/JCO.21.02800  0.313
2021 Yang DD, Chen MH, Wu J, Braccioforte MH, Moran BJ, D'Amico AV. The risk of death from prostate cancer in men with Gleason score 3+4 prostate cancer treated using brachytherapy with or without a short course of androgen deprivation therapy. Urologic Oncology. PMID 34315661 DOI: 10.1016/j.urolonc.2021.06.022  0.342
2021 Sheikh MT, Ibrahim JG, Gelfond JA, Sun W, Chen MH. Joint modelling of longitudinal and survival data in the presence of competing risks with applications to prostate cancer data. Statistical Modelling. 21: 72-94. PMID 34177376 DOI: 10.1177/1471082X20944620  0.329
2021 Kim DW, Chen MH, Wu J, Huland H, Graefen M, Tilki D, D'Amico AV. Prostate-specific antigen levels of ≤4 and >4 ng/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer. Cancer. PMID 34101827 DOI: 10.1002/cncr.33503  0.316
2021 King MT, Chen MH, Collette L, Neven A, Bolla M, D'Amico AV. Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer: A Secondary Analysis of 2 Randomized Clinical Trials. Jama Network Open. 4: e2111092. PMID 33999161 DOI: 10.1001/jamanetworkopen.2021.11092  0.312
2021 Bitterman DS, Chen MH, Wu J, Renshaw AA, Loffredo M, Kantoff PW, Small EJ, D'Amico AV. Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality. Cancer. PMID 33823065 DOI: 10.1002/cncr.33543  0.341
2020 Kim S, Chen MH, Ibrahim J, Shah A, Lin J. Bayesian flexible hierarchical skew heavy-tailed multivariate meta regression models for individual patient data with applications. Statistics and Its Interface. 13: 485-500. PMID 32855761 DOI: 10.4310/Sii.2020.V13.N4.A6  0.302
2020 Kim DW, Chen MH, Huland H, Graefen M, Tilki D, D'Amico AV. Association of Age With Risk of Adverse Pathological Findings at Radical Prostatectomy in Men With Gleason Score 6 Prostate Cancer. Jama Network Open. 3: e202041. PMID 32239219 DOI: 10.1001/jamanetworkopen.2020.2041  0.308
2020 de Castro M, Chen MH, Zhang Y, D'Amico AV. A bayesian multi-risks survival (MRS) model in the presence of double censorings. Biometrics. PMID 31994171 DOI: 10.1111/Biom.13228  0.717
2020 Yang DD, Chen M, Braccioforte MH, Moran BJ, D'Amico AV. The risk of death from prostate cancer in men with Gleason Score 3+4 prostate cancer treated using brachytherapy with or without a short course of androgen deprivation therapy. Journal of Clinical Oncology. 38: 330-330. DOI: 10.1200/Jco.2020.38.6_Suppl.330  0.448
2020 Schmidt DR, Bhagwat M, Glazer DI, Chen M, D'Amico AV. A prospective comparison of MRI-planned versus CT-planned radiotherapy for prostate cancer. Journal of Clinical Oncology. 38: 312-312. DOI: 10.1200/Jco.2020.38.6_Suppl.312  0.397
2020 Kim D, Chen M, Huland H, Graefen M, Tilki D, D'Amico AV. Advancing age and the risk of adverse pathology at radical prostatectomy in men with biopsy Gleason score 6 prostate cancer. Journal of Clinical Oncology. 38: 289-289. DOI: 10.1200/Jco.2020.38.6_Suppl.289  0.379
2020 Zhang F, Chen M, Cong XJ, Chen Q. Assessing importance of biomarkers: A Bayesian joint modelling approach of longitudinal and survival data with semi-competing risks: Statistical Modelling. DOI: 10.1177/1471082X20933363  0.302
2019 Leeman JE, Chen MH, Huland H, Graefen M, D'Amico AV, Tilki D. Advancing Age and the Odds of Upgrading and Upstaging at Radical Prostatectomy in Men with Gleason Score 6 Prostate Cancer. Clinical Genitourinary Cancer. PMID 31601512 DOI: 10.1016/J.Clgc.2019.07.018  0.421
2019 Pike LRG, Wu J, Chen MH, Loffredo M, Renshaw AA, Pfail J, Kantoff PW, D'Amico AV. Time to PSA Nadir and the Risk of Death from Prostate Cancer following Radiation and Androgen Deprivation Therapy. Urology. PMID 30664895 DOI: 10.1016/j.urology.2018.11.056  0.437
2018 Wu J, Ibrahim JG, Chen MH, Schifano ED, Fisher JD. Bayesian Modeling and Inference for Nonignorably Missing Longitudinal Binary Response Data with Applications to HIV Prevention Trials. Statistica Sinica. 28: 1929-1963. PMID 30595637 DOI: 10.5705/Ss.202016.0319  0.303
2018 Tilki D, Chen MH, Wu J, Huland H, Graefen M, Braccioforte M, Moran BJ, D'Amico AV. Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality. Jama Oncology. PMID 30452521 DOI: 10.1001/Jamaoncol.2018.4836  0.403
2018 Mahal BA, Chen MH, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV. Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 727-734. PMID 29891524 DOI: 10.6004/Jnccn.2018.7010  0.442
2018 Wang YB, Chen MH, Kuo L, Lewis PO. A New Monte Carlo Method for Estimating Marginal Likelihoods. Bayesian Analysis. 13: 311-333. PMID 29805725 DOI: 10.1214/17-Ba1049  0.305
2018 Wu J, de Castro M, Schifano ED, Chen MH. Assessing covariate effects using Jeffreys-type prior in the Cox model in the presence of a monotone partial likelihood. Journal of Statistical Theory and Practice. 12: 23-41. PMID 29805335 DOI: 10.1080/15598608.2017.1299058  0.344
2018 McDuff SGR, Chen MH, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV. Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer. Cancer. PMID 29338073 DOI: 10.1002/Cncr.31217  0.43
2018 Atkins KM, Chen M, Wu J, Renshaw AA, Loffredo M, Kantoff PW, Small EJ, D'Amico AV. Low testosterone at first PSA failure and assessment of the risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials. Journal of Clinical Oncology. 36: 45-45. DOI: 10.1200/Jco.2018.36.6_Suppl.45  0.461
2017 King MT, Chen MH, Moran BJ, Braccioforte MH, Buzurovic I, Muralidhar V, Yang DD, Mouw KW, Devlin PM, D'Amico AV, Nguyen PL, Orio PF. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. Urologic Oncology. PMID 29276060 DOI: 10.1016/J.Urolonc.2017.11.022  0.432
2017 Atkins KM, Chen MH, Wu J, Renshaw AA, Loffredo M, Kantoff PW, Small EJ, D'Amico AV. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials. Cancer. PMID 29266181 DOI: 10.1002/Cncr.31204  0.443
2017 Royce TJ, Chen MH, D'Amico AV. Validity of Surrogate End Points for Prostate Cancer-Reply. Jama Oncology. PMID 28859194 DOI: 10.1001/Jamaoncol.2017.2506  0.408
2017 Royce TJ, Chen MH, Wu J, Loffredo M, Renshaw AA, Kantoff PW, D'Amico AV. Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial. Jama Oncology. PMID 28097317 DOI: 10.1001/Jamaoncol.2016.5983  0.421
2017 Patel SA, Chen M, Loffredo M, Renshaw AA, Kantoff PW, D'Amico AV. Impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or without androgen deprivation therapy for unfavorable-risk prostate cancer. Journal of Clinical Oncology. 20: 68-68. DOI: 10.1200/Jco.2017.35.6_Suppl.68  0.446
2017 Royce TJ, Chen M, Wu J, Loffredo M, Renshaw AA, Kantoff PW, D'Amico AV. A comparison of surrogate endpoints for all cause mortality in men with localized unfavorable-risk prostate cancer. Journal of Clinical Oncology. 35: 21-21. DOI: 10.1200/Jco.2017.35.6_Suppl.21  0.459
2016 Mihalcik SA, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Comorbidity and the Receipt of Curative Therapy for Favorable-risk Prostate Cancer Prior to and Following the Publication of PIVOT. European Urology Focus. PMID 28753752 DOI: 10.1016/j.euf.2016.02.007  0.421
2016 Rose BS, Chen MH, Wu J, Braccioforte MH, Moran BJ, Doseretz DE, Katin MJ, Ross RH, Salenius SA, D'Amico AV. Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing Mortality. International Journal of Radiation Oncology, Biology, Physics. 96: 778-784. PMID 27788950 DOI: 10.1016/J.Ijrobp.2016.08.014  0.414
2016 Giacalone NJ, Wu J, Chen MH, Renshaw A, Loffredo M, Kantoff PW, D'Amico AV. Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27601545 DOI: 10.1200/Jco.2016.68.4530  0.43
2016 Kovtun KA, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer. Cancer. PMID 27490845 DOI: 10.1002/Cncr.30224  0.426
2016 Martin NE, Chen MH, Zhang D, Richie JP, D'Amico AV. Unfavorable Intermediate-Risk Prostate Cancer and the Odds of Upgrading to Gleason 8 or Higher at Prostatectomy. Clinical Genitourinary Cancer. PMID 27426058 DOI: 10.1016/J.Clgc.2016.06.001  0.442
2016 Huynh MA, Chen MH, Wu J, Braccioforte MH, Moran BJ, D'Amico AV. Influence of Comorbidity on the Risk of Mortality in Men With Unfavorable-Risk Prostate Cancer Undergoing High-Dose Radiation Therapy Alone. International Journal of Radiation Oncology, Biology, Physics. PMID 27209511 DOI: 10.1016/J.Ijrobp.2016.03.004  0.419
2016 Xiang M, Wang PX, Wang AB, Zhang XJ, Zhang Y, Zhang P, Mei FH, Chen MH, Li H. Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis. Journal of Hepatology. PMID 26860405 DOI: 10.1016/j.jhep.2016.02.002  0.583
2016 Dyer MA, Chen M, Braccioforte MH, Moran BJ, D'Amico AV. Comorbidity and androgen deprivation therapy use in men undergoing high-dose radiation for unfavorable intermediate- and high-risk prostate cancer. Journal of Clinical Oncology. 34: 41-41. DOI: 10.1200/Jco.2016.34.2_Suppl.41  0.418
2016 Huynh MA, Chen M, Wu J, Braccioforte MH, Moran BJ, D'Amico AV. Comorbidity and the risk of all-cause and prostate cancer–specific mortality in men with unfavorable risk prostate cancer undergoing high dose radiation therapy alone. Journal of Clinical Oncology. 34: 207-207. DOI: 10.1200/Jco.2016.34.2_Suppl.207  0.447
2016 Warren LE, Chen M, Denham JW, Steigler A, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV. Gleason score and the risk of cause-specific and all-cause mortality following radiation with or without 6 months of androgen deprivation therapy for men with unfavorable-risk prostate cancer Journal of Clinical Oncology. 5: 171-171. DOI: 10.1200/Jco.2016.34.2_Suppl.171  0.447
2016 Sanford NN, Chen M, Loffredo MJ, Renshaw AA, Kantoff PW, D'Amico AV. Duration of the anti-androgen in men undergoing six months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death. Journal of Clinical Oncology. 34: 5070-5070. DOI: 10.1200/Jco.2016.34.15_Suppl.5070  0.429
2016 Warren LEG, Chen M, Denham JW, Steigler AB, Renshaw AA, Loffredo M, Kantoff PW, D’Amico AV. Gleason score and the risk of cause-specific and all-cause mortality following radiation with or without 6 months of androgen deprivation therapy for men with unfavorable-risk prostate cancer Journal of Radiation Oncology. 5: 301-308. DOI: 10.1007/S13566-016-0260-9  0.447
2016 Dyer MA, Chen M, Braccioforte MH, Moran BJ, D’Amico AV. Comorbidity and androgen deprivation therapy use in men undergoing high-dose radiation for unfavorable-risk prostate cancer Journal of Radiation Oncology. 5: 293-300. DOI: 10.1007/S13566-016-0253-8  0.442
2015 M'lan CE, Chen MH. Objective Bayesian Inference for Bilateral Data. Bayesian Analysis. 10: 139-170. PMID 27057264 DOI: 10.1214/14-Ba890  0.311
2015 Sinha A, Chi Z, Chen MH. BAYESIAN INFERENCE OF HIDDEN GAMMA WEAR PROCESS MODEL FOR SURVIVAL DATA WITH TIES. Statistica Sinica. 25: 1613-1635. PMID 26576105 DOI: 10.5705/Ss.2012.351  0.636
2015 Shi M, Lin XD, Vasilakis N, Tian JH, Li CX, Chen LJ, Eastwood G, Diao XN, Chen MH, Chen X, Qin XC, Widen SG, Wood TG, Tesh RB, Xu J, et al. Divergent viruses discovered in arthropods and vertebrates revise the evolutionary history of the Flaviviridae and related viruses. Journal of Virology. PMID 26491167 DOI: 10.1128/Jvi.02036-15  0.58
2015 D'Amico AV, Chen MH, Renshaw A, Loffredo M, Kantoff PW. Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. Jama. 314: 1291-3. PMID 26393854 DOI: 10.1001/Jama.2015.8577  0.454
2015 Huynh MA, Chen MH, Wu J, Braccioforte MH, Moran BJ, D'Amico AV. Gleason Score 3 + 5 or 5 + 3 versus 4 + 4 Prostate Cancer: The Risk of Death. European Urology. PMID 26388503 DOI: 10.1016/J.Eururo.2015.08.054  0.437
2015 Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapy. Brachytherapy. PMID 26361718 DOI: 10.1016/J.Brachy.2015.08.004  0.437
2015 Vance TM, Azabdaftari G, Pop EA, Lee SG, Su LJ, Fontham ET, Bensen JT, Steck SE, Arab L, Mohler JL, Chen MH, Koo SI, Chun OK. Thioredoxin 1 in Prostate Tissue Is Associated with Gleason Score, Erythrocyte Antioxidant Enzyme Activity, and Dietary Antioxidants. Prostate Cancer. 2015: 728046. PMID 26357575 DOI: 10.1155/2015/728046  0.412
2015 Ennis KY, Chen MH, Smith GC, D'Amico AV, Zhang Y, Quinn SA, Ryemon SN, Goltz D, Harrison LB, Ennis RD. The Impact of Economic Recession on the Incidence and Treatment of Cancer. Journal of Cancer. 6: 727-33. PMID 26185534 DOI: 10.1200/Jco.2011.29.15_Suppl.6005  0.655
2015 Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer. Jama Oncology. 1: 334-40. PMID 26181182 DOI: 10.1001/Jamaoncol.2014.284  0.434
2015 Braunstein LZ, Chen MH, Dosoretz DE, Salenius SA, Katin MJ, Nanda A, D'Amico AV. Whole Pelvis Versus Prostate-Only Radiotherapy With or Without Short-Course Androgen Deprivation Therapy and Mortality Risk. Clinical Genitourinary Cancer. PMID 26003267 DOI: 10.1016/J.Clgc.2015.04.010  0.427
2015 Keane FK, Chen MH, Zhang D, Moran BJ, Braccioforte MH, D'Amico AV. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease. Cancer. PMID 25925789 DOI: 10.1002/Cncr.29420  0.423
2015 Cheney MD, Zhang D, Chen MH, Loffredo MJ, Richie JP, D'Amico AV. Greatest Percentage Involved Core Length and Risk of Clinically Significant Prostate-Specific Antigen Failure After Radical Prostatectomy. Clinical Genitourinary Cancer. 13: 338-43. PMID 25862320 DOI: 10.1016/J.Clgc.2015.02.012  0.426
2015 Chandra RA, Chen MH, Zhang D, Loffredo M, D'Amico AV. Age, Comorbidity, and the Risk of Prostate Cancer-Specific Mortality in Men With Biopsy Gleason Score 4+3: Implications on Patient Selection for Multiparametric MRI. Clinical Genitourinary Cancer. 13: 400-5. PMID 25862319 DOI: 10.1016/J.Clgc.2015.03.001  0.422
2015 Chen J, Zhang Y, Liu J, Chen MH, Guo YL, Zhu CG, Xu RX, Dong Q, Li JJ. Role of lipoprotein(a) in predicting the severity of new on-set coronary artery disease in type 2 diabetics: A Gensini score evaluation. Diabetes & Vascular Disease Research. 12: 258-64. PMID 25861813 DOI: 10.1177/1479164115579004  0.606
2015 de Castro M, Chen MH, Zhang Y. Bayesian path specific frailty models for multi-state survival data with applications. Biometrics. PMID 25762198 DOI: 10.1111/Biom.12298  0.651
2015 Aizer AA, Gu X, Chen MH, Choueiri TK, Martin NE, Efstathiou JA, Hyatt AS, Graham PL, Trinh QD, Hu JC, Nguyen PL. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 61-8. PMID 25583770 DOI: 10.6004/Jnccn.2015.0009  0.412
2015 Zhang Y, Kundu B, Zhong M, Huang T, Li J, Chordia MD, Chen MH, Pan D, He J, Shi W. PET imaging detection of macrophages with a formyl peptide receptor antagonist. Nuclear Medicine and Biology. 42: 381-6. PMID 25532700 DOI: 10.1016/J.Nucmedbio.2014.12.001  0.583
2015 Parekh A, Chen MH, Graham P, Mahal BA, Hirsch AE, Nakabayashi M, Evan C, Kantoff PW, Martin NE, Nguyen PL. Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less. Clinical Genitourinary Cancer. 13: e1-6. PMID 25103271 DOI: 10.1016/J.Clgc.2014.06.016  0.401
2015 Raldow AC, Zhang D, Chen M, Braccioforte MH, Moran BJ, D'Amico AV. Are men with favorable intermediate-risk prostate cancer candidates for active surveillance? Journal of Clinical Oncology. 33: 82-82. DOI: 10.1200/Jco.2015.33.7_Suppl.82  0.41
2015 Keane FK, Chen M, Zhang D, Moran BJ, Braccioforte MH, D'Amico AV. Short-course hormonal therapy and the risk of death from prostate cancer in men with intermediate-risk prostate cancer undergoing high-dose radiation therapy. Journal of Clinical Oncology. 33: 27-27. DOI: 10.1200/Jco.2015.33.7_Suppl.27  0.413
2015 Warren LE, Chen M, Denham JW, Steigler A, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV. Gleason grade 5 and the risk of death from prostate cancer following radiation with or without 6 months of conventional androgen deprivation therapy. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E16099  0.432
2015 Braunstein LZ, Chen M, Dosoretz DE, Salenius S, Katin M, Nanda A, D'Amico AV. Abstract 3438: Whole pelvis versus prostate-only radiotherapy with or without short course androgen deprivation therapy and mortality risk Cancer Research. 75: 3438-3438. DOI: 10.1158/1538-7445.Am2015-3438  0.415
2014 Huang QJ, Zhang Y, Li XL, Li S, Guo YL, Zhu CG, Xu RX, Jiang LX, Chen MH, Li JJ. Clinical features of coronary artery ectasia in the elderly. Journal of Geriatric Cardiology : Jgc. 11: 185-91. PMID 25278965 DOI: 10.11909/j.issn.1671-5411.2014.03.012  0.607
2014 Pashtan I, Chen MH, D'Amico AV. The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5 ng/ml. Cancer Epidemiology. 38: 613-8. PMID 25164550 DOI: 10.1016/J.Canep.2014.07.007  0.425
2014 Kang YJ, Diao XN, Zhao GY, Chen MH, Xiong Y, Shi M, Fu WM, Guo YJ, Pan B, Chen XP, Holmes EC, Gillespie JJ, Dumler SJ, Zhang YZ. Extensive diversity of Rickettsiales bacteria in two species of ticks from China and the evolution of the Rickettsiales. Bmc Evolutionary Biology. 14: 167. PMID 25073875 DOI: 10.1186/S12862-014-0167-2  0.574
2014 Chen J, Chen MH, Li S, Guo YL, Zhu CG, Xu RX, Zhang Y, Sun J, Qing P, Liu G, Li JJ. Usefulness of the neutrophil-to-lymphocyte ratio in predicting the severity of coronary artery disease: a Gensini score assessment. Journal of Atherosclerosis and Thrombosis. 21: 1271-82. PMID 25069816 DOI: DN/JST.JSTAGE/jat/25940  0.588
2014 Huang J, Luo YL, Hao Y, Zhang YL, Chen PX, Xu JW, Chen MH, Luo YF, Zhong NS, Xu J, Zhou WL. Cellular mechanism underlying hydrogen sulfide induced mouse tracheal smooth muscle relaxation: role of BKCa. European Journal of Pharmacology. 741: 55-63. PMID 25034810 DOI: 10.1016/j.ejphar.2014.07.004  0.584
2014 Braunstein LZ, Chen MH, Loffredo M, Kantoff PW, D'Amico AV. Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer. Prostate Cancer. 2014: 230812. PMID 24864213 DOI: 10.1155/2014/230812  0.39
2014 Tanguturi SK, Chen MH, Loffredo M, Richie JP, D'Amico AV. Evaluating the Impact of PSA as a Selection Criteria for Nerve Sparing Radical Prostatectomy in a Screened Cohort. Prostate Cancer. 2014: 395078. PMID 24829803 DOI: 10.1155/2014/395078  0.364
2014 Rose BS, Chen MH, Zhang D, Hirsch MS, Richie JP, Chang SL, Hegde JV, Loffredo MJ, D'Amico AV. Maximum tumor diameter and the risk of prostate-specific antigen recurrence after radical prostatectomy. Clinical Genitourinary Cancer. 12: e173-9. PMID 24787967 DOI: 10.1016/J.Clgc.2014.03.008  0.39
2014 Yang XQ, Liu JY, Li XC, Chen MH, Zhang YL. Key amino acid associated with acephate detoxification by Cydia pomonella carboxylesterase based on molecular dynamics with alanine scanning and site-directed mutagenesis. Journal of Chemical Information and Modeling. 54: 1356-70. PMID 24749772 DOI: 10.1021/ci500159q  0.58
2014 Phillips JG, Aizer AA, Chen MH, Zhang D, Hirsch MS, Richie JP, Tempany CM, Williams S, Hegde JV, Loffredo MJ, D'Amico AV. The effect of differing Gleason scores at biopsy on the odds of upgrading and the risk of death from prostate cancer. Clinical Genitourinary Cancer. 12: e181-7. PMID 24721618 DOI: 10.1016/J.Clgc.2014.02.008  0.329
2014 Martin NE, Chen MH, Beard CJ, Nguyen PL, Loffredo MJ, Renshaw AA, Kantoff PW, D'Amico AV. Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators. Prostate Cancer. 2014: 912943. PMID 24701353 DOI: 10.1155/2014/912943  0.433
2014 Chandra RA, Chen MH, Zhang D, Loffredo M, D'Amico AV. Evidence suggesting that obesity prevention measures may improve prostate cancer outcomes using data from a prospective randomized trial. Prostate Cancer. 2014: 478983. PMID 24693436 DOI: 10.1155/2014/478983  0.389
2014 Mirabeau-Beale K, Chen MH, D'Amico AV. Prior-cancer diagnosis in men with nonmetastatic prostate cancer and the risk of prostate-cancer-specific and all-cause mortality. Isrn Oncology. 2014: 736163. PMID 24634786 DOI: 10.1155/2014/736163  0.421
2014 Keane FK, Chen MH, Zhang D, Loffredo MJ, Kantoff PW, Renshaw AA, D'Amico AV. The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer. 120: 1787-93. PMID 24604289 DOI: 10.1002/cncr.28609  0.417
2014 Cheney MD, Chen MH, Zhang D, Phillips JG, Loffredo MJ, D'Amico AV. Greatest percentage of involved core length and the risk of death from prostate cancer in men with highest Gleason score ≥ 7. Clinical Genitourinary Cancer. 12: 234-40. PMID 24594503 DOI: 10.1016/J.Clgc.2014.01.006  0.419
2014 Zhang Y, Chen MH, Ibrahim JG, Zeng D, Chen Q, Pan Z, Xue X. Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching. Lifetime Data Analysis. 20: 76-105. PMID 23543121 DOI: 10.1007/S10985-013-9254-8  0.65
2014 Aizer AA, Chen MH, Hattangadi J, D'Amico AV. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer. Bju International. 113: 43-50. PMID 23473327 DOI: 10.1111/J.1464-410X.2012.11789.X  0.449
2014 Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease. European Urology. 65: 177-85. PMID 22981136 DOI: 10.1016/J.Eururo.2012.08.070  0.4
2014 Cheney MD, Chen M, Zhang D, Phillips JG, Loffredo MJ, D'Amico AV. Greatest percent involved core length and the risk of death from prostate cancer in men with highest Gleason score 7 or higher. Journal of Clinical Oncology. 32: 164-164. DOI: 10.1200/Jco.2014.32.4_Suppl.164  0.433
2014 Braunstein LZ, Chen M, Loffredo MJ, Kantoff PW, D'Amico AV. Obesity and the odds of weight gain following androgen deprivation therapy for prostate cancer: Toward a risk adapted approach for ADT use. Journal of Clinical Oncology. 32: 5045-5045. DOI: 10.1200/Jco.2014.32.15_Suppl.5045  0.424
2014 Phillips J, Chen M, Zhang D, Loffredo M, Kantoff P, D'Amico A. Percent Positive Biopsy Cores and the Risk of Death from Prostate Cancer in Men Treated with Radiation and Androgen Deprivation Therapy International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.05.637  0.458
2014 Phillips J, Aizer A, Chen M, Zhang D, Hirsch M, Richie J, Tempany C, Williams S, Hegde J, Loffredo M, D′Amico A. The Impact of Differing Gleason Scores at Biopsy on the Odds of Upgrading and the Risk of Death From Prostate Cancer International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.05.1286  0.424
2014 Ziehr DR, Chen M, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, Hyatt AS, Beard CJ, D'Amico AV, Hoffman KE, Martin NE, Nguyen PL. Association of Androgen Deprivation Therapy with Excess Cardiovascular-Specific Mortality in Men with Prostate Cancer International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.05.100  0.424
2014 Phillips JG, Chen M, Zhang D, Loffredo M, Kantoff PW, D’Amico AV. Percent positive biopsy cores and the risk of death from prostate cancer in men with unfavorable-risk prostate cancer Journal of Radiation Oncology. 3: 307-312. DOI: 10.1007/S13566-014-0158-3  0.445
2013 Chen MH, Moran BJ, Braccioforte MH, D'Amico AV. Intermediate versus short-course hormone therapy and mortality in men with high-risk prostate cancer treated with radiation therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 83. PMID 28137130 DOI: 10.1200/Jco.2013.31.6_Suppl.83  0.378
2013 Chen MH, Beard C, Nguyen PL, Loffredo M, Renshaw AA, Kantoff PW, D'Amico AV. Age, comorbidity, and the risk of death in men with PSA failure following radiation therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 82. PMID 28137129 DOI: 10.1200/Jco.2013.31.6_Suppl.82  0.395
2013 Chen MH, D'Amico AV. Prior cancer diagnosis in men with nonmetastatic prostate cancer and the risk of prostate cancer specific and all-cause mortality. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 70. PMID 28137083 DOI: 10.1200/jco.2013.31.6_suppl.70  0.311
2013 Zhou JH, Ni ZH, Mei CL, Yu XQ, Liu FY, Miao LN, Liu ZH, Yuan WJ, Zhang AP, Lin HL, Chen MH, Chen JH, Zhang JY, He YN, Chen J, et al. Efficacy and safety of Changfu peritoneal dialysis solution: a multi-center prospective randomized controlled trial. Chinese Medical Journal. 126: 4204-9. PMID 24238498 DOI: 10.3760/cma.j.issn.0366-6999.20131722  0.579
2013 Kim MB, Chen MH, de Castro M, Loffredo M, Kantoff PW, D'Amico AV. Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial. Cancer. 119: 3280-6. PMID 23798006 DOI: 10.1002/Cncr.28202  0.398
2013 Parekh A, Chen MH, D'Amico AV, Dosoretz DE, Ross R, Salenius S, Graham PL, Beckman JA, Beard CJ, Choueiri TK, Ennis RD, Hoffman KE, Hu JC, Ma J, Martin NE, et al. Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. Brachytherapy. 12: 415-21. PMID 23651926 DOI: 10.1016/j.brachy.2013.02.005  0.331
2013 Nanda A, Chen MH, Moran BJ, Braccioforte MH, D'Amico AV. Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy. International Journal of Radiation Oncology, Biology, Physics. 85: e209-15. PMID 23332383 DOI: 10.1016/J.Ijrobp.2012.11.039  0.43
2013 Hegde JV, Chen MH, Mulkern RV, Fennessy FM, D'Amico AV, Tempany CM. Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 85: e101-7. PMID 23040223 DOI: 10.1016/J.Ijrobp.2012.08.032  0.389
2013 Phillips JG, Aizer AA, Chen M, Hirsch MS, Richie JP, Tempany CM, Hegde J, Loffredo M, D'Amico AV. Detecting lower in addition to the highest Gleason score prostate cancer on core biopsy and the odds of upgrading at radical prostatectomy. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E16026  0.424
2013 Aizer AA, Phillips J, Chen M, Zhang D, Loffredo M, D'Amico AV. Detecting lower in addition to the highest Gleason score prostate cancer on core biopsy and the risk of prostate cancer-specific mortality. Journal of Clinical Oncology. 31: 5051-5051. DOI: 10.1200/Jco.2013.31.15_Suppl.5051  0.44
2012 Nguyen PL, Chen MH, Zhang Y, Tempany CM, Cormack RA, Beard C, Hurwitz MD, Suh WW, D'Amico AV. Long-term results of MRI-guided partial prostate brachytherapy for favorable-risk prostate cancer: Implications for focal therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 114. PMID 28143026 DOI: 10.1200/jco.2012.30.5_suppl.114  0.696
2012 Hattangadi JA, Chen MH, Sun L, D'Amico AV. Early detection of high-grade prostate cancer using digital rectal examination in men with a normal PSA and risk of death. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 147. PMID 27968244 DOI: 10.1200/Jco.2012.30.5_Suppl.147  0.43
2012 Nguyen PL, Chen MH, Zhang Y, Tempany CM, Cormack RA, Beard C, Hurwitz MD, Suh WW, D'Amico AV. Long-term results of MRI-guided partial prostate brachytherapy for favorable-risk prostate cancer: Implications for focal therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 114. PMID 27967968 DOI: 10.1200/Jco.2012.30.5_Suppl.114  0.718
2012 Parekh A, Chen MH, Hoffman KE, Choueiri TK, Hu JC, Bennett CL, Kattan MW, Sartor AO, Stein K, D'Amico AV, Nguyen PL. Incidence of reduced penis size among men with recurrent prostate cancer previously treated with surgery, radiation plus androgen deprivation, or radiation alone. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 38. PMID 27967841 DOI: 10.1200/Jco.2012.30.5_Suppl.38  0.409
2012 Wu MC, Tang ZY, Ye SL, Fan J, Qin SK, Yang JM, Chen MS, Chen MH, Lv MD, Ma KS, Wu YL, Chen Y, Qian GJ, Lu SC, Zheng JS, et al. Expert consensus on local ablation therapies for primary liver cancer. Chinese Clinical Oncology. 1: 11. PMID 25842069 DOI: 10.3978/j.issn.2304-3865.2012.06.01  0.62
2012 Russo AL, Chen MH, Aizer AA, Hattangadi JA, D'Amico AV. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM). Bju International. 110: 973-9. PMID 22954029 DOI: 10.1111/J.1464-410X.2012.11470.X  0.446
2012 Nguyen PL, Chen MH, Zhang Y, Tempany CM, Cormack RA, Beard CJ, Hurwitz MD, Suh WW, D'Amico AV. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. The Journal of Urology. 188: 1151-6. PMID 22901567 DOI: 10.1016/J.Juro.2012.06.010  0.702
2012 Hattangadi JA, Chen MH, D'Amico AV. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death. Bju International. 110: 1636-41. PMID 22757982 DOI: 10.1111/J.1464-410X.2012.11354.X  0.435
2012 Martin NE, Chen MH, Nguyen PL, Beard CJ, Loffredo MJ, Kantoff PW, D'Amico AV. Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade. Bju International. 110: 1252-6. PMID 22564379 DOI: 10.1111/J.1464-410X.2012.11118.X  0.395
2012 Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, Katin M, Salenius S, D'Amico AV. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer. Bju International. 110: 1116-21. PMID 22540922 DOI: 10.1111/J.1464-410X.2012.11012.X  0.34
2012 Chen RC, Zhang Y, Chen MH, McMahon E, Loffredo M, McPherson CP, Nguyen AU, Nguyen PL, D'Amico AV. Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial. Bju International. 110: 1690-5. PMID 22502770 DOI: 10.1111/J.1464-410X.2012.11117.X  0.653
2012 Tseng YD, Chen MH, Beard CJ, Martin NE, Orio PF, Loffredo M, Renshaw AA, Choueiri TK, Hu JC, Kantoff PW, D'Amico AV, Nguyen PL. Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. The Journal of Urology. 187: 2068-73. PMID 22498212 DOI: 10.1016/j.juro.2012.01.073  0.321
2012 Ge M, Chen MH. Bayesian inference of the fully specified subdistribution model for survival data with competing risks. Lifetime Data Analysis. 18: 339-63. PMID 22484596 DOI: 10.1007/S10985-012-9221-9  0.751
2012 Wattson DA, Chen MH, Moul JW, Moran BJ, Dosoretz DE, Robertson CN, Polascik TJ, Braccioforte MH, Salenius SA, D'Amico AV. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection. International Journal of Radiation Oncology, Biology, Physics. 82: e773-9. PMID 22300573 DOI: 10.1016/J.Ijrobp.2011.11.023  0.421
2012 Rosenberg JE, Chen MH, Nguyen PL, Braccioforte MH, Moran BJ, D'Amico AV. Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer. Clinical Genitourinary Cancer. 10: 21-5. PMID 22130293 DOI: 10.1016/j.clgc.2011.10.003  0.328
2012 D'Amico AV, Chen MH, de Castro M, Loffredo M, Lamb DS, Steigler A, Kantoff PW, Denham JW. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. The Lancet. Oncology. 13: 189-95. PMID 22112793 DOI: 10.1016/S1470-2045(11)70295-9  0.445
2012 Nguyen PL, Chen MH, Hoffman KE, Chen RC, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, D'Amico AV. Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. Bju International. 110: 201-5. PMID 22085233 DOI: 10.1111/J.1464-410X.2011.10709.X  0.323
2012 Kang J, Chen MH, Zhang Y, Moran BJ, Dosoretz DE, Katin MJ, Braccioforte MH, Salenius SA, D'Amico AV. Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 82: e463-7. PMID 21944463 DOI: 10.1016/J.Ijrobp.2011.07.003  0.691
2012 Park JJ, Chen M, Loffredo M, D’Amico AV. Prostate-Specific Antigen Velocity Before And After Elimination Of Factors That Can Confound The Prostate-Specific Antigen Level International Journal of Radiation Oncology Biology Physics. 82: 1217-1221. PMID 21640512 DOI: 10.1016/J.Ijrobp.2011.04.019  0.386
2012 Ding L, Zhang FB, Liu H, Gao X, Bi HC, Wang XD, Chen BL, Zhang Y, Zhao LZ, Zhong GP, Hu PJ, Chen MH, Huang M. Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease. Inflammatory Bowel Diseases. 18: 63-73. PMID 21381155 DOI: 10.1002/ibd.21676  0.602
2012 Pashtan I, Chen M, Sun L, D'Amico A. 1916 The Impact Of Psa Level On The Risk Of Prostate Cancer Specific Mortality In Men With A Normal Psa The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.2073  0.431
2012 Hegde J, Chen M, Mulkern RV, Fennessy FM, Tempany CM, D'Amico AV. Preoperative 3-Tesla multiparametric endorectal MRI findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer International Journal of Radiation Oncology Biology Physics. 84. DOI: 10.1016/J.Ijrobp.2012.07.949  0.405
2012 Parekh A, Chen M, Dosoretz DE, Ross R, Salenius S, Graham PL, D'Amico AV, Nguyen PL. Identification of Comorbidities That Place Men at Highest Risk of Harm From Androgen Deprivation Therapy for Prostate Cancer International Journal of Radiation Oncology Biology Physics. 84. DOI: 10.1016/J.Ijrobp.2012.07.244  0.439
2012 Mirabeau-Beale KL, Chen M, Sun L, D'Amico AV. Metachronous Cancer Diagnosis in Men With Prostate Cancer and the Risk of Prostate Cancer-specific Mortality: A Competing Risks Analysis International Journal of Radiation Oncology Biology Physics. 84. DOI: 10.1016/J.Ijrobp.2012.07.1439  0.415
2012 Russo AL, Chen M, Sun L, Aizer A, Hattangadi J, D'Amico AV. Advancing Age Within Established Gleason Score Categories and the Risk of Prostate Cancer-specific Mortality International Journal of Radiation Oncology Biology Physics. 84. DOI: 10.1016/J.Ijrobp.2012.07.1426  0.417
2011 Arvold ND, Chen M, Moul JW, Moran BJ, Dosoretz DE, Banez LL, Katin MJ, Braccioforte MH, D'Amico AV. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low- or intermediate-risk disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 198. PMID 27968470 DOI: 10.1200/Jco.2011.29.7_Suppl.198  0.426
2011 D'Amico AV, Chen MH, Crook J, Armstrong JG, Malone S, Steigler A, Dunne M, Kantoff PW, Denham JW. Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4682-7. PMID 22042952 DOI: 10.1200/Jco.2011.37.0726  0.437
2011 Das S, Chen MH, Warren N, Hodgson M. Do associations between employee self-reported organizational assessments and attitudinal outcomes change over time? An analysis of four Veterans Health Administration surveys using structural equation modelling. Health Economics. 20: 1507-22. PMID 22025392 DOI: 10.1002/Hec.1692  0.566
2011 Mitin T, Chen MH, Zhang Y, Moran BJ, Dosoretz DE, Katin MJ, Braccioforte MH, Salenius SA, D'Amico AV. Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapy. The Journal of Urology. 186: 2233-7. PMID 22019035 DOI: 10.1016/J.Juro.2011.07.072  0.69
2011 D'Amico AV, Chen MH, Dosoretz D, Katin M, Salenius S, Ross R, Goldhaber SZ. Coronary artery revascularization and the risk of death in men with prostate cancer. The Journal of Urology. 186: 898-902. PMID 21788044 DOI: 10.1016/J.Juro.2011.04.076  0.447
2011 Arvold ND, Chen MH, Moul JW, Moran BJ, Dosoretz DE, Bañez LL, Katin MJ, Braccioforte MH, D'Amico AV. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. The Journal of Urology. 186: 91-6. PMID 21571341 DOI: 10.1016/J.Juro.2011.03.003  0.45
2011 Winkfield KM, Chen MH, Dosoretz DE, Salenius SA, Katin M, Ross R, D'Amico AV. Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics. 81: e345-50. PMID 21514066 DOI: 10.1016/J.Ijrobp.2011.02.022  0.43
2011 Chen MH, Ibrahim JG, Lam P, Yu A, Zhang Y. Bayesian design of noninferiority trials for medical devices using historical data. Biometrics. 67: 1163-70. PMID 21361889 DOI: 10.1111/J.1541-0420.2011.01561.X  0.607
2011 Hattangadi JA, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Predictors of the use of supplemental androgen suppression therapy and external beam radiation in men with high-risk prostate cancer undergoing brachytherapy in community practice. Brachytherapy. 10: 369-75. PMID 21349778 DOI: 10.1016/J.Brachy.2011.01.004  0.419
2011 Crawford ED, Grubb R, Black A, Andriole GL, Chen MH, Izmirlian G, Berg CD, D'Amico AV. Comorbidity and mortality results from a randomized prostate cancer screening trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 355-61. PMID 21041707 DOI: 10.1200/Jco.2010.30.5979  0.402
2011 Kim S, Chen M, Dey DK. A new threshold regression model for survival data with a cure fraction. Lifetime Data Analysis. 17: 101-122. PMID 20414804 DOI: 10.1007/S10985-010-9166-9  0.356
2011 Wattson DA, Chen M, Moul JW, Moran BJ, Dosoretz DE, Robertson CN, Polascik TJ, Braccioforte MH, Salenius SA, D'Amico AV. The Number of High-Risk Factors and the Risk of Prostate Cancer-Specific Mortality Following Radical Prostatectomy or Brachytherapy International Journal of Radiation Oncology Biology Physics. 81. DOI: 10.1016/J.Ijrobp.2011.06.716  0.409
2011 Tseng YD, Chen M, Loffredo M, Kantoff PW, Beard CJ, Martin NE, Orio PF, D'Amico AV, Nguyen PL. Post-Treatment Prostate-Specific Antigen Nadir is Predictive of All-Cause Mortality: A Reanalysis of the Dana Farber Cancer Institute Radiation With or Without Androgen Deprivation Therapy Randomized Trial International Journal of Radiation Oncology Biology Physics. 81. DOI: 10.1016/J.Ijrobp.2011.06.681  0.41
2010 D'Amico AV, Braccioforte MH, Moran BJ, Chen MH. Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease. Alzheimer Disease and Associated Disorders. 24: 85-9. PMID 20556875 DOI: 10.1097/Wad.0B013E31819Cb8F4  0.407
2010 D’Amico AV, Chen M, Sun L, Lee WR, Mouraviev V, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW. Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. Bjui. 106: 1618-1622. PMID 20553253 DOI: 10.1111/J.1464-410X.2010.09447.X  0.434
2010 Cheung AK, Chen MH, Moran BJ, Braccioforte MH, Dosoretz DE, Salenius S, Katin M, Ross R, D'Amico AV. The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American Brachytherapy Society Guideline statement. Brachytherapy. 9: 145-50. PMID 20346894 DOI: 10.1016/J.Brachy.2009.08.001  0.44
2010 Hoffman KE, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin MJ, Ross R, D'Amico AV. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer. Cancer. 116: 2590-5. PMID 20310055 DOI: 10.1002/cncr.24974  0.337
2010 Hayes JH, Chen MH, Moran BJ, Braccioforte MH, Dosoretz DE, Salenius S, Katin MJ, Ross R, Choueiri TK, D'Amico AV. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. Bju International. 106: 979-85. PMID 20230380 DOI: 10.1111/J.1464-410X.2010.09273.X  0.422
2010 Choueiri TK, Chen MH, D'Amico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death Cancer. 116: 1887-1892. PMID 20162710 DOI: 10.1002/Cncr.25013  0.409
2010 Dosoretz AM, Chen M, Salenius SA, Ross RH, Dosoretz DE, Katin MJ, Mantz C, Nakfoor BM, D'Amico AV. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy. Cancer. 116: 837-842. PMID 20052734 DOI: 10.1002/Cncr.24750  0.448
2010 Nguyen PL, Chen MH, Beard CJ, Suh WW, Choueiri TK, Efstathiou JA, Hoffman KE, Loffredo M, Kantoff PW, D'Amico AV. Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. Cancer. 116: 610-5. PMID 19957321 DOI: 10.1002/cncr.24818  0.312
2010 D'Amico AV, Braccioforte MH, Moran BJ, Chen MH. Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 77: 1329-37. PMID 19879061 DOI: 10.1016/J.Ijrobp.2009.06.051  0.403
2010 Nguyen PL, Chen MH, Beard CJ, Suh WW, Renshaw AA, Loffredo M, McMahon E, Kantoff PW, D'Amico AV. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. International Journal of Radiation Oncology, Biology, Physics. 77: 1046-52. PMID 19864082 DOI: 10.1016/J.Ijrobp.2009.06.038  0.415
2010 Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 77: 147-52. PMID 19744800 DOI: 10.1016/J.Ijrobp.2009.04.085  0.451
2010 Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 76: 1439-44. PMID 19540066 DOI: 10.1016/J.Ijrobp.2009.03.034  0.446
2010 Nguyen PL, Chen MH, Renshaw AA, Loffredo M, Kantoff PW, D'Amico AV. Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations. International Journal of Radiation Oncology, Biology, Physics. 76: 337-41. PMID 19395186 DOI: 10.1016/J.Ijrobp.2009.01.045  0.411
2010 D'Amico AV, Chen M, Kantoff PW. Reply to M. Kumar et al Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.29.5642  0.431
2010 D'Amico A, Chen M, Sun L, Lee WR, Mouraviev V, Robertson C, Walther P, Polascik T, Albala D, Moul J. 663 Adjuvant Versus Salvage Radiation Therapy For Prostate Cancer And The Risk Of Death The Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1050  0.422
2010 Cotter SE, Chen M, Moul JW, Lee WR, Koontz BF, Anscher MS, D'Amico AV. Salvage Radiation in Men with PSA Failure following Radical Prostatectomy and the Risk of Death International Journal of Radiation Oncology Biology Physics. 78. DOI: 10.1016/J.Ijrobp.2010.07.370  0.343
2010 Hattangadi JA, Chen M, Braccioforte MH, Moran BJ, D'Amico AV. Predictors of the Use of Supplemental Androgen Suppression Therapy (AST) and External Beam Radiation Therapy (EBRT) in Men with High-risk Prostate Cancer (PC) Undergoing Brachytherapy International Journal of Radiation Oncology Biology Physics. 78. DOI: 10.1016/J.Ijrobp.2010.07.1347  0.409
2010 Nanda A, Chen M, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Whole Pelvis vs. Prostate Only Irradiation and Mortality in Men with Prostate Cancer Treated with or without Hormonal Therapy International Journal of Radiation Oncology Biology Physics. 78. DOI: 10.1016/J.Ijrobp.2010.07.1320  0.43
2009 Winkfield KM, Chen M, Dosoretz DE, Salenius SA, Katin MJ, Ross R, D'Amico AV. Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5068. PMID 27964249 DOI: 10.1200/Jco.2009.27.15_Suppl.5068  0.42
2009 Chen MH, Zhang YQ, Zhu QJ, Xue SF, Tao Z. 2-(2-Fur-yl)-1H-imidazo[4,5-f][1,10]phenanthroline-3,7-diium dichloride monohydrate. Acta Crystallographica. Section E, Structure Reports Online. 65: o341. PMID 21581942 DOI: 10.1107/S1600536809001160  0.574
2009 Wo JY, Chen MH, Nguyen PL, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV. Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6000-5. PMID 19858385 DOI: 10.1200/Jco.2009.23.6067  0.432
2009 Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. Jama. 302: 866-73. PMID 19706860 DOI: 10.1001/Jama.2009.1137  0.406
2009 D'Amico AV, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, Chen MH. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3923-8. PMID 19597029 DOI: 10.1200/Jco.2008.20.3992  0.449
2009 D'Amico AV, Chen M. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer. Journal of Clinical Oncology. 27: 3575-3576. PMID 19506151 DOI: 10.1200/Jco.2009.22.6068  0.462
2009 D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. International Journal of Radiation Oncology, Biology, Physics. 75: 10-5. PMID 19395184 DOI: 10.1016/J.Ijrobp.2008.10.082  0.425
2009 Nanda A, Chen MH, D'Amico AV. Mathematical rigor is necessary, but for men with prostate cancer, clinical relevance is the priority. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1728-9; author reply. PMID 19237624 DOI: 10.1200/Jco.2008.21.5392  0.409
2009 Chen RC, Sadetsky N, Chen MH, Carroll PR, D'Amico AV. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy. International Journal of Radiation Oncology, Biology, Physics. 75: 36-9. PMID 19233568 DOI: 10.1016/J.Ijrobp.2008.10.059  0.352
2009 Nanda A, Chen MH, Renshaw AA, D'Amico AV. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. International Journal of Radiation Oncology, Biology, Physics. 74: 1419-23. PMID 19131185 DOI: 10.1016/J.Ijrobp.2008.10.027  0.443
2009 Kim S, Xi Y, Chen M. A new latent cure rate marker model for survival data The Annals of Applied Statistics. 3: 1124-1146. DOI: 10.1214/09-Aoas238  0.354
2009 Kim S, Das S, Chen M, Warren N. Bayesian Structural Equations Modeling for Ordinal Response Data with Missing Responses and Missing Covariates Communications in Statistics-Theory and Methods. 38: 2748-2768. DOI: 10.1080/03610910902936299  0.623
2009 Choueiri TK, Chen M, D'Amico AV, Sun L, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW. Prostate-Specific Antigen Recurrence After Radical Prostatectomy And The Risk Of Death The Journal of Urology. 181: 577. DOI: 10.1016/S0022-5347(09)61627-X  0.392
2009 Hoffman KE, Chen M, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. The Risk Of Prostate Cancer Death For Elderly Men With Treated High-Risk Prostate Cancer And No Or Corrected Cardiovascular Disease The Journal of Urology. 181: 207-207. DOI: 10.1016/S0022-5347(09)60596-6  0.435
2009 Nanda A, Chen M, Braccioforte MH, Moran BJ, D'Amico AV. Cardiac Comorbidity and Mortality in Men with Prostate Cancer Treated with Brachytherapy with or without Neoadjuvant Hormonal Therapy International Journal of Radiation Oncology Biology Physics. 75. DOI: 10.1016/J.Ijrobp.2009.07.218  0.406
2009 Cheung AK, Chen M, Moran BJ, Braccioforte MH, Dosoretz DE, Salenius S, Katin M, Ross R, D'Amico AV. Use of Supplemental External Beam Radiotherapy in Men with Low-risk Prostate Cancer undergoing Brachytherapy International Journal of Radiation Oncology Biology Physics. 75. DOI: 10.1016/J.Ijrobp.2009.07.1127  0.412
2008 Huang Y, Chen MH, Zhang YQ, Xue SF, Tao Z. 3a,11b-Dihydr-oxy-2-oxo-2,3,3a,11b-tetra-hydro-1H-imidazo[4,5-f][1,10]phenanthrolin-7-ium chloride. Acta Crystallographica. Section E, Structure Reports Online. 64: o1489. PMID 21203201 DOI: 10.1107/S160053680802093X  0.573
2008 D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer. 113: 3290-7. PMID 18980297 DOI: 10.1002/Cncr.23970  0.429
2008 Nguyen PL, Chen MH, Catalona WJ, Moul JW, Sun L, D'Amico AV. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. International Journal of Radiation Oncology, Biology, Physics. 73: 659-64. PMID 18692327 DOI: 10.1016/j.ijrobp.2008.05.009  0.313
2008 Martin NE, Chen MH, Catalona WJ, Loeb S, Roehl KA, D'Amico AV. The influence of serial prostate-specific antigen (PSA) screening on the PSA velocity at diagnosis. Cancer. 113: 717-22. PMID 18615505 DOI: 10.1002/cncr.23609  0.307
2008 D'Amico AV, Chen MH, Renshaw AA, Loffredo B, Kantoff PW. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2979-83. PMID 18565884 DOI: 10.1200/Jco.2007.15.9699  0.427
2008 Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Urology. 71: 136-40. PMID 18242382 DOI: 10.1016/J.Urology.2007.08.028  0.445
2008 D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. Jama. 299: 289-95. PMID 18212313 DOI: 10.1001/Jama.299.3.289  0.396
2008 Das S, Chen M, Kim S, Warren N. A Bayesian structural equations model for multilevel data with missing responses and missing covariates Bayesian Analysis. 3: 197-224. DOI: 10.1214/08-Ba308  0.613
2008 D'Amico AV, Chen M, Renshaw A, Loffredo M, Kantoff P. Androgen Suppression And Radiation Vs Radiation For Prostate Cancer: A Randomized Trial And Analysis Of The Prognostic Significance Of Comorbidity The Journal of Urology. 179: 491-491. DOI: 10.1016/S0022-5347(08)61446-9  0.392
2008 Nanda A, Chen M, Renshaw AA, D'Amico AV. PSA Recurrence in Men Following Definitive Therapy for Prostate Cancer with Gleason Score 9/10, 8, and 7 with Tertiary Grade 5 Disease International Journal of Radiation Oncology Biology Physics. 72. DOI: 10.1016/J.Ijrobp.2008.06.856  0.429
2008 D'Amico AV, Chen M. Reply to Duration of Testosterone Suppression and the Risk of Death from Prostate Cancer in Men Treated Using Radiation and 6 Months of Hormone Therapy Cancer. 112: 2323-2323. DOI: 10.1002/cncr.23426  0.316
2007 D'Amico AV, Kantoff PW, Chen M. Aspirin and Hormone Therapy for Prostate Cancer The New England Journal of Medicine. 357: 2737-2738. PMID 18160699 DOI: 10.1056/Nejmc0706698  0.369
2007 Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Journal of the National Cancer Institute. 99: 1516-24. PMID 17925537 DOI: 10.1093/Jnci/Djm168  0.435
2007 Chen MH, Zhu Z, Zhang Y, Favors S, Xu WB, Featherstone DA, Icenogle JP. An indirect immunocolorimetric assay to detect rubella virus infected cells. Journal of Virological Methods. 146: 414-8. PMID 17919742 DOI: 10.1016/j.jviromet.2007.08.021  0.58
2007 Patel AA, Chen MH, Renshaw AA, D'Amico AV. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. Jama. 298: 1533-8. PMID 17911498 DOI: 10.1001/Jama.298.13.1533  0.439
2007 D'Amico AV, Renshaw AA, Loffredo B, Chen MH. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer. 110: 1723-8. PMID 17828774 DOI: 10.1002/Cncr.22972  0.428
2007 Alexander BM, Chen M, Carroll P, D'Amico aAV. Prostate-Specific Antigen Level at Initiation of Hormonal Therapy After Prostate-Specific Antigen Failure Following Prostatectomy or Radiotherapy and Therapeutic Response Urology. 70: 320-323. PMID 17826497 DOI: 10.1016/J.Urology.2007.03.074  0.416
2007 Nguyen PL, Chen MH, Renshaw AA, Sussman B, D'Amico AV. Effect of definition of preradiotherapy prostate-specific antigen velocity on its association with prostate cancer-specific mortality and all-cause mortality. Urology. 70: 288-93. PMID 17826491 DOI: 10.1016/J.Urology.2007.03.061  0.422
2007 Nguyen PL, Chen MH, D'Amico AV, Tempany CM, Steele GS, Albert M, Cormack RA, Carr-Locke DL, Bleday R, Suh WW. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer. 110: 1485-92. PMID 17701957 DOI: 10.1002/Cncr.22934  0.419
2007 D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2420-5. PMID 17557956 DOI: 10.1200/Jco.2006.09.3369  0.376
2007 D'Amico AV, Chen MH, Catalona WJ, Sun L, Roehl KA, Moul JW. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer. 110: 56-61. PMID 17530618 DOI: 10.1002/cncr.22737  0.317
2007 Banerjee T, Chen M, Dey DK, Kim S. Bayesian analysis of generalized odds-rate hazards models for survival data Lifetime Data Analysis. 13: 241-260. PMID 17401683 DOI: 10.1007/S10985-007-9035-3  0.34
2007 D'Amico AV, Denham JW, Bolla M, Collette L, Lamb DS, Tai KH, Steigler A, Chen MH. Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate Cancer. 109: 2004-2010. PMID 17397033 DOI: 10.1002/Cncr.22628  0.431
2007 Krejcarek SC, Chen MH, Renshaw AA, Loffredo M, Sussman B, D'Amico AV. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer. Urology. 69: 515-9. PMID 17382156 DOI: 10.1016/J.Urology.2006.11.009  0.434
2007 Efstathiou JA, Chen MH, Renshaw AA, Loffredo MJ, D'Amico AV. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer. Cancer. 109: 1493-8. PMID 17340594 DOI: 10.1002/Cncr.22564  0.413
2007 D'Amico AV, McLeod DG, Carroll PR, Cullen J, Chen MH. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality. Cancer. 109: 1290-5. PMID 17315162 DOI: 10.1002/Cncr.22550  0.446
2007 D’Amico AV, Denham J, Bolla M, Collette L, Lamb DS, Tai K, Steigler A, Chen M. 730: Short- Versus Long-Term Androgen Suppression Plus External Beam Radiation Therapy and Survival in Men with High-Risk Adenocarcinoma of the Prostate The Journal of Urology. 177: 245-245. DOI: 10.1016/S0022-5347(18)30970-4  0.385
2007 Tsai HK, D'Amico AV, Sadetsky N, Chen M, Carroll PR. 378: Androgen Deprivation Therapy for Prostate Cancer and the Risk of Cardiac Mortality The Journal of Urology. 177: 125-126. DOI: 10.1016/S0022-5347(18)30631-1  0.415
2007 Patel AA, Chen M, Renshaw AA, D'Amico AV. Tertiary Gleason Grade 5 on Prostate Needle Biopsy and Recurrence Following Definitive Therapy in Men With Gleason Score 7 Prostate Cancer International Journal of Radiation Oncology Biology Physics. 69. DOI: 10.1016/J.Ijrobp.2007.07.166  0.431
2007 Martin NE, Chen M, Catalona WJ, Loeb S, Roehl KA, D'Amico AV. The Influence of Serial Prostate-Specific Antigen Screening on the Pre-Diagnostic PSA Velocity Level at Diagnosis International Journal of Radiation Oncology Biology Physics. 69. DOI: 10.1016/J.Ijrobp.2007.07.164  0.346
2007 Suh WW, Chen M, Nguyen PL, Tempany CM, Steele GS, Albert M, Cormack R, Carr-Locke DL, Bleday R, D'Amico AV. Magnetic Resonance Image Guided Salvage Brachytherapy Following Radiation in Select Men who Initially Presented With Favorable-risk Prostate Cancer: A Prospective Phase II Study International Journal of Radiation Oncology Biology Physics. 69. DOI: 10.1016/J.Ijrobp.2007.07.1389  0.401
2006 Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer. 107: 2597-603. PMID 17039498 DOI: 10.1002/Cncr.22279  0.448
2006 Petit JH, Chen MH, Loffredo M, Sussman B, Renshaw AA, D'Amico AV. Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer. Cancer. 107: 2180-5. PMID 17009323 DOI: 10.1002/Cncr.22243  0.429
2006 D'Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen MH. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4190-5. PMID 16943536 DOI: 10.1200/Jco.2006.06.8239  0.429
2006 Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology. 68: 342-7. PMID 16904449 DOI: 10.1016/J.UROLOGY.2006.02.030  0.306
2006 Rodrigues NA, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer. Cancer. 107: 514-20. PMID 16795068 DOI: 10.1002/cncr.22018  0.319
2006 D'Amico AV, Kantoff P, Loffredo M, Renshaw AA, Loffredo B, Chen MH. Predictors of mortality after prostate-specific antigen failure International Journal of Radiation Oncology Biology Physics. 65: 656-660. PMID 16682147 DOI: 10.1016/J.Ijrobp.2006.01.053  0.397
2006 Rozhansky F, Chen M, Cox MC, Dahut W, Figg WD, D'Amico AV. Prostate‐specific antigen velocity and survival for patients with hormone‐refractory metastatic prostate carcinoma Cancer. 106: 63-67. PMID 16333854 DOI: 10.1002/Cncr.21576  0.409
2006 D'Amico AV, Loffredo M, Renshaw AA, Chen M. 663: Prostate-Specific Antigen Failure and All Cause Mortality The Journal of Urology. 175: 214-214. DOI: 10.1016/S0022-5347(18)32909-4  0.369
2006 Efstathiou JA, Chen M, Renshaw AA, Loffredo M, D’Amico AV. 2309: The Influence of Body Mass Index on PSA Failure Following Androgen Suppression and Radiation Therapy for Localized Prostate Cancer International Journal of Radiation Oncology Biology Physics. 66. DOI: 10.1016/J.Ijrobp.2006.07.717  0.39
2006 Petit JH, Chen M, Loffredo M, Sussman B, Renshaw AA, D’Amico AV. 2245 : Prostate-Specific Antigen Recurrence and Mortality Following Conventional Dose Radiation Therapy in Select Men With Low-Risk Prostate Cancer International Journal of Radiation Oncology Biology Physics. 66. DOI: 10.1016/J.Ijrobp.2006.07.652  0.436
2006 Krejcarek SC, Chen M, Renshaw A, Loffredo M, Sussman B, D’Amico AV. 2242 : Pre-Treatment PSA Velocity and the Probability of Detecting High-Grade Prostate Cancer International Journal of Radiation Oncology Biology Physics. 66. DOI: 10.1016/J.Ijrobp.2006.07.648  0.403
2006 D’Amico AV, Dedham JW, Crook J, Chen M, Goldhaber SZ, Lamb DS, Malone S, Ludgate C, Steigler A, Kantoff PW. 2239 : The Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of a Fatal Myocardial Infarction International Journal of Radiation Oncology Biology Physics. 66. DOI: 10.1016/J.Ijrobp.2006.07.645  0.377
2005 Dvorak T, Chen MH, Renshaw AA, Loffredo M, Richie JP, D'Amico AV. Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer. Urology. 66: 1024-8. PMID 16286117 DOI: 10.1016/J.Urology.2005.05.037  0.425
2005 Beard C, Chen M, Cote K, Loffredo M, Renshaw A, Hurwitz M, D’Amico AV. Pretreatment predictors of posttreatment PSA doubling times for patients undergoing three-dimensional conformal radiotherapy for clinically localized prostate cancer. Urology. 66: 1020-1023. PMID 16286116 DOI: 10.1016/J.Urology.2005.05.039  0.414
2005 Zhou P, Chen M, McLeod D, Carroll PR, Moul JW, D’Amico AV. Predictors of Prostate Cancer–Specific Mortality After Radical Prostatectomy or Radiation Therapy Journal of Clinical Oncology. 23: 6992-6998. PMID 16192586 DOI: 10.1200/Jco.2005.01.2906  0.409
2005 Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, D'Amico AV. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6556-60. PMID 16170163 DOI: 10.1200/Jco.2005.20.966  0.444
2005 D’Amico AV, Chen M, Cox MC, Dahut W, Figg WD. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer. Urology. 66: 571-576. PMID 16140080 DOI: 10.1016/J.Urology.2005.03.083  0.436
2005 D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy Journal of the American Medical Association. 294: 440-447. PMID 16046650 DOI: 10.1001/Jama.294.4.440  0.454
2005 Woel R, Beard C, Chen M, Hurwitz M, Loffredo M, McMahon E, Ching J, Lopes L, D’Amico AV. Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization International Journal of Radiation Oncology Biology Physics. 62: 392-396. PMID 15890580 DOI: 10.1016/J.Ijrobp.2004.10.003  0.328
2005 D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. The Journal of Urology. 173: 1572-6. PMID 15821488 DOI: 10.1097/01.JU.0000157569.59229.72  0.311
2005 D’Amico AV, Chen M, Roehl KA, Catalona WJ. 1678: Identifying Patients at Risk for Benign Versus Life Shortening Postoperative Prostate-Specific Antigen Failure The Journal of Urology. 173: 455-455. DOI: 10.1016/S0022-5347(18)35800-2  0.389
2005 Efstathiou JA, Chen M, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D’Amico AV. Evidence to Support that Serial Screening Decreases Prostate Cancer-Specific Mortality International Journal of Radiation Oncology Biology Physics. 63. DOI: 10.1016/J.Ijrobp.2005.07.191  0.385
2004 D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH, Iversen P, Gelmann EP, Sellers WR. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy Journal of Urology. 172: S42-S47. PMID 15535442 DOI: 10.1097/01.ju.0000141845.99899.12  0.317
2004 D'Amico AV, Renshaw AA, Cote K, Hurwitz M, Beard C, Loffredo M, Chen MH. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease Journal of Clinical Oncology. 22: 3726-3732. PMID 15365069 DOI: 10.1200/Jco.2004.01.164  0.427
2004 D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. The New England Journal of Medicine. 351: 125-35. PMID 15247353 DOI: 10.1056/NEJMOA032975  0.312
2004 D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure Journal of the National Cancer Institute. 96: 509-515. PMID 15069112 DOI: 10.1093/Jnci/Djh086  0.391
2004 Shen ZY, Zhang Y, Chen JY, Chen MH, Shen J, Luo WH, Zeng Y. Intratumoral injection of arsenic to enhance antitumor efficacy in human esophageal carcinoma cell xenografts. Oncology Reports. 11: 155-9. PMID 14654919  0.583
2004 D'Amico AV, Chen M, Roehl KA, Catalona WJ. 1189: Identifying Potentially Life Threatening Prostate Cancer at Diagnosis The Journal of Urology. 171: 314-314. DOI: 10.1016/S0022-5347(18)38426-X  0.387
2004 Woel RF, Beard C, Chen M, Hurwitz M, Loffredo M, McMahon E, Ching J, Lopes L, D’Amico AV. Acute gastrointestinal, genitourinary, and dermatologic toxicity during dose escalated 3DCRT using an intra-rectal balloon for prostate gland localization and immobilization International Journal of Radiation Oncology Biology Physics. 60. DOI: 10.1016/J.Ijrobp.2004.07.559  0.345
2004 D'Amico AV, Renshaw AA, Cote K, Hurwitz M, Beard C, Loffredo M, Chen M. The impact of the percent of positive prostate biopsies on prostate cancer-specific mortality for patients with low or favorable intermediate risk disease International Journal of Radiation Oncology Biology Physics. 60. DOI: 10.1016/J.Ijrobp.2004.07.353  0.436
2003 D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen M. Surrogate End Point for Prostate Cancer–Specific Mortality After Radical Prostatectomy or Radiation Therapy Journal of the National Cancer Institute. 95: 1376-1383. PMID 13130113 DOI: 10.1093/Jnci/Djg043  0.441
2003 Albert M, Tempany CM, Schultz D, Chen MH, Cormack RA, Kumar S, Hurwitz MD, Beard C, Tuncali K, O'Leary M, Topulos GP, Valentine K, Lopes L, Kanan A, Kacher D, et al. Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy. Cancer. 98: 949-54. PMID 12942561 DOI: 10.1002/Cncr.11595  0.41
2003 Chen Y, Wang BE, Jia JD, Qian LX, Wang TL, Chen MH, Chen GY, He W, Ding HG, Yin SS, Zhang Y, Dong Z. [Noninvasive evaluation of liver fibrosis in chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology. 11: 354-7. PMID 12837216  0.597
2003 D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen M. Cancer-Specific Mortality After Surgery or Radiation for Patients With Clinically Localized Prostate Cancer Managed During the Prostate-Specific Antigen Era Journal of Clinical Oncology. 21: 2163-2172. PMID 12775742 DOI: 10.1200/Jco.2003.01.075  0.433
2003 D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure Journal of Urology. 169: 1320-1324. PMID 12629352 DOI: 10.1097/01.Ju.0000049200.30192.D1  0.445
2003 D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH. Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma Cancer. 97: 56-62. PMID 12491505 DOI: 10.1002/Cncr.11053  0.408
2003 Chen M, Dey DK. Variable selection for multivariate logistic regression models Journal of Statistical Planning and Inference. 111: 37-55. DOI: 10.1016/S0378-3758(02)00284-7  0.343
2002 Ung JO, Richie JP, Chen MH, Renshaw AA, D'Amico AV. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era Urology. 60: 458-463. PMID 12350484 DOI: 10.1016/S0090-4295(02)01814-9  0.397
2002 Yoon JH, Chen MH, Renshaw AA, Richie JP, D'Amico AV. Predictive factor analysis as the basis for the clinical utility of percent positive prostate biopsies in patients with intermediate-risk prostate cancer. Urology. 60: 454-7. PMID 12350483 DOI: 10.1016/S0090-4295(02)01770-3  0.426
2002 D'Amico AV, Chen MH, Oh-Ung J, Renshaw AA, Cote K, Loffredo M, Richie JP. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era International Journal of Radiation Oncology Biology Physics. 54: 436-441. PMID 12243819 DOI: 10.1016/S0360-3016(02)02940-1  0.411
2002 D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era Cancer. 95: 281-286. PMID 12124827 DOI: 10.1002/Cncr.10657  0.434
2002 D'Amico AV, Saegaert T, Chen MH, Renshaw AA, George D, Oh W, Kantoff PW. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer Cancer. 95: 275-280. PMID 12124826 DOI: 10.1002/Cncr.10673  0.443
2002 Linson PW, Lee AK, Doytchinova T, Chen MH, Weinstein MH, Richie JP, D'Amico AV. Percentage of core lengths involved with prostate cancer: does it add to the percentage of positive prostate biopsies in predicting postoperative prostate-specific antigen outcome for men with intermediate-risk prostate cancer? Urology. 59: 704-8. PMID 11992844 DOI: 10.1016/S0090-4295(01)01665-X  0.323
2002 Chen MH, Ibrahim JG, Sinha D. Bayesian inference for multivariate survival data with a cure fraction Journal of Multivariate Analysis. 80: 101-126. DOI: 10.1006/Jmva.2000.1975  0.306
2001 D’Amico AV, Wu Y, Chen M, Nash M, Renshaw AA, Richie JP. Perineural Invasion As A Predictor Of Biochemical Outcome Following Radical Prostatectomy For Select Men With Clinically Localized Prostate Cancer The Journal of Urology. 165: 126-129. PMID 11125380 DOI: 10.1097/00005392-200101000-00031  0.418
2001 DAmico AV, Saegart T, Chen M, Renshaw AA, George D, Oh W, Kantoff PW. The impact of anemia on psa outcome following radiation and androgen suppression therapy in patients with high-risk prostate cancer International Journal of Radiation Oncology Biology Physics. 51: 113. DOI: 10.1016/S0360-3016(01)02031-4  0.422
2000 AVDMD, Wu Y, Chen M, Nash BSM, Renshaw AA, Richie JP. Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a Gleason score ≤ 7 Cancer. 89: 1810-1817. PMID 11042577 DOI: 10.1002/1097-0142(20001015)89:8<1810::Aid-Cncr22>3.0.Co;2-9  0.4
2000 D’Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen M, Hurwitz M, Kantoff PW, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Utilizing Predictions of Early Prostate-Specific Antigen Failure to Optimize Patient Selection for Adjuvant Systemic Therapy Trials Journal of Clinical Oncology. 18: 3240-3246. PMID 10986056 DOI: 10.1200/Jco.2000.18.18.3240  0.409
2000 D’Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen M, Art M, Tomaszewski JE, Wein A. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology. 55: 572-577. PMID 10736506 DOI: 10.1016/S0090-4295(99)00479-3  0.418
1999 Sinha D, Chen M, Ghosh SK. Bayesian analysis and model selection for interval-censored survival data. Biometrics. 55: 585-590. PMID 11318218 DOI: 10.1111/J.0006-341X.1999.00585.X  0.31
1999 Chen M, Dey DK, Shao Q. A New Skewed Link Model for Dichotomous Quantal Response Data Journal of the American Statistical Association. 94: 1172-1186. DOI: 10.1080/01621459.1999.10473872  0.336
1999 Chen MH, Shao QM. Properties of Prior and Posterior Distributions for Multivariate Categorical Response Data Models Journal of Multivariate Analysis. 71: 277-296. DOI: 10.1006/Jmva.1999.1846  0.338
1998 D'Amico AV, Desjardin A, Chen M, Paik BSS, Schultz D, Renshaw AA, Loughlin KR, Richie JP. Analyzing outcome-based staging for clinically localized adenocarcinoma of the prostate. Cancer. 83: 2172-2180. PMID 9827722 DOI: 10.1002/(Sici)1097-0142(19981115)83:10<2172::Aid-Cncr16>3.0.Co;2-K  0.352
1998 AVDMD, Desjardin A, Chung BSA, Chen M, Schultz D, Whittington R, Malkowicz SB, Wein A, Tomaszewski JE, Renshaw AA, Loughlin K, Richie JP. Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. Cancer. 82: 1887-1896. PMID 9587121 DOI: 10.1002/(Sici)1097-0142(19980515)82:10<1887::Aid-Cncr11>3.0.Co;2-P  0.407
1998 Chen M, Schmeiser B. Toward Black-Box Sampling: A Random-Direction Interior-Point Markov Chain Approach Journal of Computational and Graphical Statistics. 7: 1-22. DOI: 10.1080/10618600.1998.10474758  0.617
1998 D'amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen M, Tomaszewski JE, Wein A. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. The Journal of Urology. 160: 2096-2101. DOI: 10.1016/S0022-5347(01)62251-1  0.432
1997 D'Amico AV, Chang H, Holupka E, Renshaw A, Desjarden A, Chen M, Loughlin KR, Richie JP. Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. Urology. 49: 385-391. PMID 9123703 DOI: 10.1016/S0090-4295(96)00509-2  0.407
1996 Chen MH, Schmeiser BW. General Hit-and-Run Monte Carlo sampling for evaluating multidimensional integrals Operations Research Letters. 19: 161-169. DOI: 10.1016/0167-6377(96)00030-2  0.61
1993 Chen M, Schmeiser B. Performance of the Gibbs, Hit-and-Run, and Metropolis Samplers Journal of Computational and Graphical Statistics. 2: 251-272. DOI: 10.1080/10618600.1993.10474611  0.616
1989 Zhou QX, Xue CS, Wang DN, Zhang YJ, Gao LJ, Chen MH. Effects of ginsenosides on release of [3H]norepinephrine from rat vas deferens and portal vein. Zhongguo Yao Li Xue Bao = Acta Pharmacologica Sinica. 10: 26-30. PMID 2816397  0.576
1989 Meng XJ, Sun Y, Chen MH, Liu ZH, Zhang YX, Li XZ, Li K, Han RC, Si JY, Hu LY. Viral etiology of cervical carcinoma. Human papilloma virus and herpes simplex virus type 2. Chinese Medical Journal. 102: 94-9. PMID 2550184  0.577
1987 Sun Y, Chen MH, Zhang YX, Xiao H, Liu HY, Chen X, Zeng Y. [Promoting effect of the Chinese medicinal herb, wikstroemia chamaedaphne and tung oil extracts on carcinoma of the uterine cervix induced by HSV-2 or methylcholanthrene (MCA) in mice]. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]. 9: 345-7, 20. PMID 2838237  0.58
1980 Chen MH, Sun Y, Zhou QD, Zhang YX. [Experimental induction of cervical carcinoma in mice by genital herpes simplex virus (author's transl)]. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]. 2: 259-62. PMID 7297399  0.577
Show low-probability matches.